Capasso Planning Partners LLC raised its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 20.4% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 10,513 shares of the company’s stock after acquiring an additional 1,778 shares during the period. Johnson & Johnson comprises 1.0% of Capasso Planning Partners LLC’s portfolio, making the stock its 25th biggest position. Capasso Planning Partners LLC’s holdings in Johnson & Johnson were worth $1,630,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of JNJ. Scotia Capital Inc. raised its stake in shares of Johnson & Johnson by 1.6% during the 4th quarter. Scotia Capital Inc. now owns 1,105,147 shares of the company’s stock worth $195,247,000 after purchasing an additional 17,440 shares in the last quarter. Wisconsin Capital Management LLC raised its stake in shares of Johnson & Johnson by 0.8% during the 1st quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock worth $2,437,000 after purchasing an additional 127 shares in the last quarter. Boyar Asset Management Inc. raised its stake in shares of Johnson & Johnson by 1.1% during the 1st quarter. Boyar Asset Management Inc. now owns 19,191 shares of the company’s stock worth $2,975,000 after purchasing an additional 201 shares in the last quarter. Van Hulzen Asset Management LLC raised its stake in shares of Johnson & Johnson by 31.8% during the 1st quarter. Van Hulzen Asset Management LLC now owns 161,743 shares of the company’s stock worth $25,052,000 after purchasing an additional 39,032 shares in the last quarter. Finally, Duality Advisers LP bought a new stake in Johnson & Johnson in the 4th quarter valued at $4,342,000. Institutional investors own 67.57% of the company’s stock.
Insider Activity at Johnson & Johnson
In related news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock valued at $7,928,856 over the last ninety days. 0.20% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Johnson & Johnson Stock Performance
JNJ opened at $174.48 on Friday. The firm has a market cap of $453.43 billion, a P/E ratio of 35.32, a price-to-earnings-growth ratio of 2.91 and a beta of 0.55. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The business’s fifty day moving average is $161.76 and its 200-day moving average is $161.21.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.59 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.76 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be paid a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.73%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What Are Dividend Contenders? Investing in Dividend Contenders
- MarketBeat Week in Review – 7/24 – 7/28
- Pros And Cons Of Monthly Dividend Stocks
- Can SAIA Continue its Stratospheric Rally?
- How to Build Wealth with the Dividend Aristocrat Index
- Why Markets Are Loving Exxon Mobil, Despite The Earnings Dip
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
